EP3939587A1 — Gaboxadol for use in the treatment of depression associated with fmr1-premutation syndrome
Assigned to Ovid Therapeutics Inc · Expires 2022-01-19 · 4y expired
What this patent protects
The invention relates to a composition comprising gaboxadol or a pharmaceutically acceptable salt thereof for use in a method of treating FMR1-premutation syndrome, the method comprising administering the composition to a patient in need thereof such as to administer to the patie…
USPTO Abstract
The invention relates to a composition comprising gaboxadol or a pharmaceutically acceptable salt thereof for use in a method of treating FMR1-premutation syndrome, the method comprising administering the composition to a patient in need thereof such as to administer to the patient 1 mg to 30 mg gaboxadol or pharmaceutically acceptable salt.
Drugs covered by this patent
- Ztalmy (GANAXOLONE) · Marinus
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.